Johnson & Johnson (NYSE: JNJ) Q1 2026 Results were officially released today, signaling a powerful start to the fiscal year with a 9.9% increase in reported sales. The healthcare giant reported total revenue of $24.1 billion, driven by strong performance across its Innovative Medicine and MedTech segments. Following this momentum, the company has raised its full-year 2026 guidance, reflecting confidence in its diverse portfolio and late-stage pipeline.
Strong Financial Performance in Q1 2026
The Johnson & Johnson Q1 2026 Results highlight a year of “accelerated growth and impact,” according to CEO Joaquin Duato. While GAAP net earnings saw a decline to $5.2 billion due to one-time litigation items and special charges compared to the previous year, the adjusted operational performance remained stellar.
Key financial metrics from the report include:
- Reported Sales: $24.1 Billion (9.9% increase)
- Adjusted Diluted EPS: $2.70
- Innovative Medicine Sales: $15.4 Billion (11.2% increase)
- MedTech Sales: $8.6 Billion (7.7% increase)
Clinical Data and Pipeline Milestones
A significant portion of the Johnson & Johnson Q1 2026 Results success is attributed to clinical breakthroughs. The company received several FDA approvals and reported positive Phase 3 data that will sustain long-term growth. Most notably, the approval of ICOTYDE (icotrokinra) as the first-and-only targeted oral peptide for plaque psoriasis marks a major shift in immunology.
Learn More: Johnson & Johnson Announces $2 Billion Investment in North Carolina Manufacturing Facility
Key Clinical Trial Results (Oncology & Immunology)
| Product | Indication | Clinical Milestone / Outcome |
| ICOTYDE™ | Plaque Psoriasis | 49% of patients achieved PASI 100 (complete clearance) at Week 52. |
| RYBREVANT® FASPRO | Head & Neck Cancer | 56% Overall Response Rate (ORR) in first-line recurrent/metastatic settings. |
| TECVAYLI® + DARZALEX® | Multiple Myeloma | 83% reduction in risk of disease progression or death in 2nd-line treatment. |
MedTech Innovation Data
| Platform | Technology | Performance Metric |
| VARIPULSE™ Pro | Pulsed Field Ablation | 84.2% freedom from atrial arrhythmia recurrence at 12 months. |
| TECNIS PureSee™ | Intraocular Lens | Enhanced vision range for cataract patients with reduced halo/glare. |
Learn More: Johnson & Johnson to Acquire Halda Therapeutics for $3.05 Billion, Bolstering Oncology Pipeline
Key Product Revenue (Innovative Medicine)
The Johnson & Johnson Q1 2026 Results were heavily influenced by the performance of the oncology portfolio, particularly the continued dominance of DARZALEX.
| Product | Therapeutic Area | Q1 2026 Revenue | Year-over-Year Change |
| DARZALEX® | Oncology | $3.96 Billion | +22.5% |
| STELARA® | Immunology | $656 Million | -59.7% |
| TREMFYA® | Immunology | $985 Million | +14.2% |
| CARVYKTI® | Oncology | $412 Million | +82.0% |
| ERLEADA® | Oncology | $745 Million | +18.4% |
| SPRAVATO® | Neuroscience | $288 Million | +34.1% |
Segment Sales Breakdown (Q1 2026)
| Business Segment | Q1 2026 Revenue (Millions) | Q1 2025 Revenue (Millions) | Reported Growth | Operational Growth |
| Innovative Medicine | $15,426 | $13,873 | 11.2% | 7.4% |
| MedTech | $8,636 | $8,020 | 7.7% | 4.6% |
| Worldwide Total | $24,062 | $21,893 | 9.9% | 6.4% |
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Future Outlook and 2026 Guidance
As part of the Johnson & Johnson Q1 2026 Results announcement, the company updated its full-year 2026 outlook. J&J now expects reported sales to fall between $100.3 billion and $101.3 billion, with an adjusted operational EPS range of $11.45 to $11.65. This upward revision is supported by the rapid adoption of CARVYKTI and the resilience of the MedTech cardiovascular portfolio.
